Specific Aim 1. To evaluate the efficacy of TNF antagonist action in BPH/LUTS Specific Aim 2.
Define the consequences of TNF antagonist therapy on prostate tissue Specific Aim 3. Identify
genetic predictors to stratify patients with differential response to TNF-antagonist therapy.
Phase:
Phase 2
Details
Lead Sponsor:
NorthShore University HealthSystem
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)